Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Pages 1195-1201 , November 2009

Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations

  • James D. Lewis

      Affiliations

    • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    • Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests Address requests for reprints to: James D. Lewis, MD, MSCE, University of Pennsylvania, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021. fax: (215) 573-0813
    • ,
  • Oren Abramson

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Monina Pascua

      Affiliations

    • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Liyan Liu

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Laura M. Asakura

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Fernando S. Velayos

      Affiliations

    • Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, California
    • ,
  • Susan M. Hutfless

      Affiliations

    • Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
    • ,
  • James E. Alison

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, California
    • ,
  • Lisa J. Herrinton

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This article has an accompanying continuing medical education activity on page 1142. Learning Objectives—At the end of this activity the learner should recognize the time frame for development of cytopenias after thiopurine therapy and appreciate the duration and potential for complications with leukopenia.

 Conflicts of interest The authors disclose the following: James Lewis served as a consultant to Prometheus for legal matters and Susan Hutfless owns stock in GlaxoSmithKline. The remaining authors disclose no conflicts.

 Funding This work was supported by a grant from the Centers for Disease Control (UO1 DP000340) and in part by the National Institutes of Health (grants K24 DK078228 and T32 DK007740).

 To view this article's video abstract, go to the AGA's YouTube Channel.

PII: S1542-3565(09)00675-2

doi: 10.1016/j.cgh.2009.07.019

Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Pages 1195-1201 , November 2009

Article Tools